(Q30725001)

English

Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

Factors associated with withdrawal of the anti-TNFα biologics in the treatment of rheumatic diseases: data from the Hong Kong Biologics Registry (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382315%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Pui-Shan Julia Chan

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382315%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382315%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

Ka Lai Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382315%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Ka Wing Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382315%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Hong Kong Society of Rheumatology

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382315%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

language of work or name

1 reference

based on heuristic

inferred from title

publication date

30 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 June 2017

International Journal of Rheumatic Diseases

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382315%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

17 Suppl 3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382315%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

1-8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382315%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China.

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with specia

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Treatment with tumor necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT.

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy: results from the Danish nationwide DANBIO registry

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0.

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Overview of safety of non-biologic and biologic DMARDs

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide D

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: an Asian perspective.

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1111%2F1756-185X.12264

21 January 2018

Identifiers

10.1111/1756-185X.12264

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382315%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24382315%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30725001&oldid=1979565469"